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A commentary on
Aspirin-triggered resolvin D1 reduces
mucosal inflammation and promotes res-
olution in a murine model of acute lung
injury
by Eickmeier, O., Seki, H., Haworth, O.,
Hilberath, J. N., Gao, F., Uddin, M.,
et al. (2012). Mucosal Immunol. doi:
10.1038/mi.2012.66
Acute lung injury (ALI), a syndrome
of respiratory failure, is a major clini-
cal problem in the United States. With
a high incidence rate, affecting nearly
200,000 annually and a significant mor-
bidity and mortality rate, ALI repre-
sents a significant source of health care
expenditure with a cost of 3.5–6 billion
dollars annually (Treggiari et al., 2004;
Rubenfeld et al., 2005; Raghavendran
et al., 2011). Clinically, ALI presents as a
decrease in the partial pressure of oxygen
per fraction of inspired oxygen with-
out the presence of left arterial hyper-
tension (Tomashefski, 2000). ALI is also
characterized by pulmonary edema, dete-
rioration of the alveolar-capillary mem-
brane and an aggressive inflammatory
response. Acute insults that affect the
continuity of the alveolar-capillary mem-
brane, such as aspiration of gastric con-
tent, sepsis, and hyperoxic therapy lead
to ALI (Dos Santos and Slutsky, 2006;
Kolliputi et al., 2010). The alveolar mem-
brane is an intricate system that not
only regulates gas exchange, but also
provides a complex defense mechanism
against foreign particles and organisms.
Pneumocytes, unique cells in the alveolar
epithelium, are responsible for facilitat-
ing gas exchange, regulating fluid trans-
port, and secreting surfactant to reduce
alveolar surface tension. When the alve-
olar barrier is disrupted, proteinaceous
exudates and extracellular components
of necrotic pneumocytes activate resi-
dent alveolar macrophages causing mas-
sive cytokine release (Ware and Matthay,
2000). The neutrophilic inflammation and
blunted gas exchange that results requires
aggressive medical care. The inflammatory
response, if left uncontrolled, can lead to
further deterioration of the lung epithe-
lium and the development of a fibro-
proliferative environment (Raghavendran
et al., 2011). While many researchers
have focused on the molecular deter-
minants of inflammation, the biochem-
ical pathways detailing the resolution
mechanism have not been thoroughly
investigated.
In the July 2012 issue of Mucosal
Immunity, Eickmeier et al., discuss the
presence of resolvins, proresolving lipid
mediators, and present exciting findings
on their role in the natural resolution of
ALI (Eickmeier et al., 2012). Resolution
phase interaction products (resolvins)
are omega-3 polyunsaturated fatty acid
derivatives of potent anti-inflammatory
precursors, eicosapentaenoic acid (EPA),
and docasahexaenoic acid (DHA) (Serhan
et al., 2002). “E-series” and “D-series”
resolvins are derived from EPA and DHA,
respectively. The airway mucosa has been
shown to be rich in DHA (Freedman
et al., 2004), however, the conversion
of DHA to D-series resolvins has not
been shown. Resolvin D1 (RvD1), a
derivative of DHA, has been found in
murine resolving inflammatory peri-
toneal exudates (Serhan et al., 2002).
To investigate the potential role that
RvD1 may play in the resolution of ALI,
Eickmeier et al. used a murine aspiration
pneumonitis acute lung injury (APALI)
model induced by hydrochloric acid
(HCl) administration into the left lung.
Picogram quantities of RvD1 were found
using metabolipidomics analysis following
HCl instillation. Immunohistochemical
analysis also showed enhanced expres-
sion of RvD1 receptor (ALX/FPR2) as
early as 2 h post-APALI. This suggested
that there indeed was a conversion of
DHA to RvD1 following lung injury.
Activation of ALX/FPR2 has previously
been demonstrated to dampen the inflam-
matory responses through blockage of
proinflammatory MAP kinase and NF-κB
signaling (Chiang et al., 2006). Utilizing an
intra-venous administration of the more
stable form of RvD1, aspirin-triggered
resolvin D1 (AT-RvD1), Eickmeier et al.
demonstrated that the conversion of
DHA in pulmonary mucosa alleviates
the effects of inflammation in APALI.
AT-RvD1 showed therapeutic effects when
given prior to or post HCl instillation.
Bronchio-alveolar lavage fluid (BALF)
collected from AT-RvD1 treated mice
contained decreased leukocytes and proin-
flammatory cytokines in comparison to
control. AT-RvD1 treated mice demon-
strated decreased lung resistance and
improved lung mechanics in comparison
to controls, a result that was correlated to
enhanced epinephrine secretion in BALF.
Utilizing conventional methods of wet-to-
dry ratio, Evans blue dye BALF content,
and FITC-dextran serum content anal-
ysis, the authors showed that AT-RvD1
restored barrier integrity in APALI mice
in comparison to control. As mentioned
previously, the anti-inflammatory effects
of ALX/FPR2 activation were shown to
be a result of reduced activation and
nuclear translocation of the transcription
factor NF-κB. Eickmeier et al., demon-
strated that mice treated with AT-RvD1
demonstrated reduced NF-κB phos-
phorylation, which is necessary for the
activation, translocation and DNA bind-
ing functions of this proinflammatory
molecule.
The work of Eickmeier et al. revealed
that RvD1 is a central mediator in the
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endogenous attenuation of inflammation
seen in APALI. In most cases of ALI, the
injury is indeed self-limiting and resolves
on its own (Dos Santos and Slutsky,
2006). This work is particularly impor-
tant because it gives insight to the mecha-
nism involved in the lung injury resolution
process. A recent clinical study demon-
strates that, ALI progression is associ-
ated with increased ventilator time and
longer intensive care unit (ICU) stays.
These patients show an enhanced proin-
flammatory cytokine profile which was
also correlated with increased morbidity
(Dolinay et al., 2012). Previous reports
have also demonstrated that ALI/ARDS
patients represent 34% of yearly costs for
all ICU trauma patients (Treggiari et al.,
2004). In the case that the ALI does not
resolve, the patient is at risk for develop-
ing acute respiratory distress syndrome in
as little as 3 days (Marshall et al., 1998).
Finding endogenous mediators that may
control the ungoverned inflammation seen
in ALI is a pivotal step to finding a treat-
ment for this disease that entails more
than just supportive care (Marshall et al.,
1998). Because of the self-limiting nature
of the APALI model, as well as the het-
erogeneously diffuse causes that may lead
to ALI, the ability of resolvins to resolve
ALI caused by other risk factors and insults
needs to be investigated. Evaluating the
effect of resolvins on other forms of ALI
represents a crucial next chapter in the
search for a cure to this debilitating dis-
ease. Furthermore, the work of Eickmeier
et al. has paved the way for the exploration
of the beneficial effects of resolvins in the
incidences of other sterile injuries, such as
atherosclerosis, gout, Alzheimer’s disease,
and diabetes. Hopefully these findings will
lead to the resolution of the war that we
wage in our bodies under inflammatory
conditions.
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